Page 671 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 40 Thalassemia Syndromes 570.e3

105. Kattamis C, Touliatos N, Haidas S, et al: Growth of children with 130. St Pierre TG, Clark PR, Chua-anusorn W, et al: Noninvasive measure-
thalassaemia: effect of different transfusion regimens. Arch Dis Child ment and imaging of liver iron concentrations using proton magnetic
45:502, 1970. resonance. Blood 105:855, 2005.
106. Cazzola M, De Stefano P, Ponchio L, et al: Relationship between trans- 131. Anderson LJ, Holden S, Davis B, et al: Cardiovascular T2-star (T2*)
fusion regimen and suppression of erythropoiesis in beta-thalassaemia magnetic resonance for the early diagnosis of myocardial iron overload.
major. Br J Haematol 89:473, 1995. Eur Heart J 22:2171, 2001.
107. Cazzola M, Borgna-Pignatti C, Locatelli F, et al: A moderate transfusion 132. Jensen PD, Jensen FT, Christensen T, et al: Evaluation of myocardial
regimen may reduce iron loading in beta-thalassemia major without iron by magnetic resonance imaging during iron chelation therapy with
producing excessive expansion of erythropoiesis. Transfusion 37:135, deferrioxamine: indication of close relation between myocardial iron
1997. content and chelatable iron pool. Blood 101:4632, 2003.
108. Piomelli S, Danoff SJ, Becker MH, et al: Prevention of bone malforma- 133. Anderson LJ, Wonke B, Prescott E, et al: Comparison of effects of
tions and cardiomegaly in Cooley’s anemia by early hypertransfusion oral deferiprone and subcutaneous desferrioxamine on myocardial iron
regimen. Ann N Y Acad Sci 165:427, 1969. concentrations and ventricular function in beta-thalassaemia. Lancet
109. Piomelli S, Karpatkin MH, Arzanian M, et al: Hypertransfusion 360:516, 2002.
regimen in patients with Cooley’s anemia. Ann N Y Acad Sci 232:186, 134. Brittenham GM, Griffith PM, Nienhuis AW, et al: Efficacy of defer-
1974. oxamine in preventing complications of iron overload in patients with
110. Propper RD, Button LN, Nathan DG: New approaches to the transfu- thalassemia major. N Engl J Med 331:567, 1994.
sion management of thalassemia. Blood 55:55, 1980. 135. Origa R, Danjou F, Cossa S, et al: Impact of heart magnetic resonance
111. Gabutti V, Piga A, Nicola P, et al: Haemoglobin levels and blood imaging on chelation choices, compliance with treatment and risk
requirement in thalassaemia. Arch Dis Child 57:156, 1982. of heart disease in patients with thalassaemia major. Br J Haematol
112. Rebulla P, Modell B: Transfusion requirements and effects in patients 163(3):400–403, 2013.
with thalassaemia major. Cooleycare Programme. Lancet 337:277, 136. Nichols-Vinueza DX, White MT, Powell AJ, et al: MRI guided iron
1991. assessment and oral chelator use improve iron status in thalassemia
113. Corash LM, Piomelli S, Chen HC, et al: Separation of erythrocytes major patients. Am J Hematol 89:684–688, 2014.
according to age on a simplified density gradient. J Lab Clin Med 137. Wood JC: Impact of iron assessment by MRI. Hematology Am Soc
84:147, 1974. Hematol Educ Program 2011:443, 2011.
114. Graziano JH, Piomelli S, Seaman C, et al: A simple technique for 138. Au WY, Lam WW, Chu W, et al: A T2* magnetic resonance imaging
preparation of young red cells for transfusion from ordinary blood study of pancreatic iron overload in thalassemia major. Haematologica
units. Blood 59:865, 1982. 93:116, 2008.
115. Cohen AR, Schmidt JM, Martin MB, et al: Clinical trial of young red 139. Noetzli LJ, Papudesi J, Coates TD, et al: Pancreatic iron loading
cell transfusions. J Pediatr 104:865, 1984. predicts cardiac iron loading in thalassemia major. Blood 114:4021,
116. Marcus RE, Wonke B, Bantock HM, et al: A prospective trial of young 2009.
red cells in 48 patients with transfusion-dependent thalassaemia. Br J 140. Brittenham GM, Farrell DE, Harris JW, et al: Magnetic-susceptibility
Haematol 60:153, 1985. measurement of human iron stores. N Engl J Med 307:1671, 1982.
117. Spanos T, Ladis V, Palamidou F, et al: The impact of neocyte transfusion 141. Fischer R, Tiemann CD, Engelhardt R, et al: Assessment of iron stores
in the management of thalassaemia. Vox Sang 70:217, 1996. in children with transfusion siderosis by biomagnetic liver susceptom-
118. Berdoukas VA, Kwan YL, Sansotta ML: A study on the value of red etry. Am J Hematol 60:289, 1999.
cell exchange transfusion in transfusion dependent anaemias. Clin Lab 142. Finch CA, Huebers H: Perspectives in iron metabolism. N Engl J Med
Haematol 8:209, 1986. 306:1520, 1982.
119. Cohen A, Freidman D, Larson P, et al: Erythrocytapheresis to reduce 143. Keberle H: The biochemistry of desferrioxamine and its relation to iron
iron loading in thalassemia. Blood 92:532a, 1998. metabolism. Ann N Y Acad Sci 119:758, 1964.
120. Erlandson ME, Walden B, Stern G, et al: Studies on congenital hemo- 144. Hershko C, Weatherall DJ: Iron-chelating therapy. Crit Rev Clin Lab
lytic syndromes, IV: Gastrointestinal absorption of iron. Blood 19:359, Sci 26:303, 1988.
1962. 145. Hershko C, Rachmilewitz EA: Mechanism of desferrioxamine-induced
121. Pippard MJ, Weatherall DJ: Iron absorption in non-transfused iron iron excretion in thalassaemia. Br J Haematol 42:125, 1979.
loading anaemias: prediction of risk for iron loading, and response to 146. Cumming RL, Millar JA, Smith JA, et al: Clinical and laboratory
iron chelation treatment, in beta thalassaemia intermedia and congeni- studies on the action of desferrioxamine. Br J Haematol 17:257,
tal sideroblastic anaemias. Haematologia (Budap) 17:17, 1984. 1969.
122. Jacobs A: Low molecular weight intracellular iron transport compounds. 147. Pippard MJ, Callender ST, Finch CA: Ferrioxamine excretion in iron-
Blood 50:433, 1977. loaded man. Blood 60:288, 1982.
123. White GP, Bailey-Wood R, Jacobs A: The effect of chelating agents on 148. Barry M, Flynn DM, Letsky EA, et al: Long-term chelation therapy in
cellular iron metabolism. Clin Sci Mol Med 50:145, 1976. thalassaemia major: effect on liver iron concentration, liver histology,
124. Hershko C, Graham G, Bates GW, et al: Non-specific serum iron in and clinical progress. Br Med J 2:16, 1974.
thalassaemia: an abnormal serum iron fraction of potential toxicity. Br 149. Seshadri R, Colebatch JH, Gordon P, et al: Long-term administra-
J Haematol 40:255, 1978. tion of desferrioxamine in thalassaemia major. Arch Dis Child 49:621,
125. Anuwatanakulchai M, Pootrakul P, Thuvasethakul P, et al: Non- 1974.
transferrin plasma iron in beta-thalassaemia/Hb E and haemoglobin H 150. Propper RD, Cooper B, Rufo RR, et al: Continuous subcutaenous
diseases. Scand J Haematol 32:153, 1984. administration of deferoxamine in patients with iron overload. N Engl
126. Wang ZJ, Haselgrove JC, Martin MB, et al: Evaluation of iron overload J Med 297:418, 1977.
by single voxel MRS measurement of liver T2. J Magn Reson Imaging 151. Bing CM: Reference on the extended stability of injectable drugs for
15:395, 2002. home care. Am J Health Syst Pharm 57:1312, 2000.
127. Clark PR, Chua-Anusorn W, St Pierre TG: Proton transverse relaxation 152. Araujo A, Kosaryan M, MacDowell A, et al: A novel delivery system
rate (R2) images of liver tissue: mapping local tissue iron concentrations for continuous desferrioxamine infusion in transfusional iron overload.
with MRI [corrected]. Magn Reson Med 49:572, 2003. Br J Haematol 93:835, 1996.
128. Clark PR, St Pierre TG: Quantitative mapping of transverse relaxivity 153. Borgna-Pignatti C, Cohen A: Evaluation of a new method of admin-
(1/T(2)) in hepatic iron overload: a single spin-echo imaging methodol- istration of the iron chelating agent deferoxamine. J Pediatr 130:86,
ogy. Magn Reson Imaging 18:431, 2000. 1997.
129. Wood JC, Enriquez C, Ghugre N, et al: MRI R2 and R2* mapping 154. Di Gregorio F, Romeo MA, Pizzarelli G, et al: An alternative to
accurately estimates hepatic iron concentration in transfusion-dependent continuous subcutaneous infusion of desferrioxamine in thalassaemic
thalassemia and sickle cell disease patients. Blood 106:1460, 2005. patients. Br J Haematol 98:601, 1997.